1887

Chapter 20 : Treatment of Intracellular Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Treatment of Intracellular Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap20-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap20-2.gif

Abstract:

The intracellular location of some bacteria remains a critical point to explain failures of antibiotic treatment from infected hosts. Parasites that multiply only within eukaryotic cells are obligate intracellular pathogens, whereas facultative intracellular pathogens may multiply in cell-free models. Bacteria can reside in phagocytic cells including neutrophils, macrophages, and monocytes or in nonphagocytic cells such as endothelial cells or in erythrocytes. Activity of antibiotics against intracellular bacteria depends on several factors, including pharmacodynamic and pharmacokinetic properties of drugs. Fluoroquinolone compounds in cells may be located both in the cytosol and lysosomes, whereas weak base antibiotics such as the aminoglycosides and the macrolides are concentrated within lysosomes. Although antibiotic susceptibility of facultative intracellular bacteria can be assessed in cell-free systems using classic MIC determination methods, the antibiotic susceptibility of obligate intracellular bacteria should be determined only in infected cell models. Animal models have been used to assess antibiotic therapeutic efficacy against intracellular pathogens. Many studies have compared the efficacy of quinolones in vitro and in vivo against intracellular pathogens. Antibiotic susceptibility of obligate intracellular bacteria, as determined using in vitro cell models is discussed in this chapter. Antibiotic treatment recommendations for intracellular pathogens are provided.

Citation: Rolain J, Raoult D. 2003. Treatment of Intracellular Infections, p 323-335. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch20
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Strategy for survival of intracellular bacteria in cells.

Citation: Rolain J, Raoult D. 2003. Treatment of Intracellular Infections, p 323-335. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch20
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Intracellular uptake and subcellular localization of antibiotics.

Citation: Rolain J, Raoult D. 2003. Treatment of Intracellular Infections, p 323-335. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch20
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555817817.chap20
1. Ahmed-Jushuf, I. H.,, O. P. Arya,, D. Hobson,, B. C. Pratt,, C. A. Hart,, S. J. How,, I. A. Tait,, and P. M. Rao. 1988. Ciprofloxacin treatment of chlamydial infections of urogenital tracts of women. Genitourin. Med. 64:1417.
2. Arain, T. M.,, A. E. Resconi,, D. C. Singh,, and C. K. Stover. 1996. Reporter gene technology to assess activity of antimycobacterial agents in macrophages. Antimicrob. Agents Chemother. 40:15421544.
3. Bakken, J. S.,, J. Krueth,, C. Wilsonnordskog,, R. L. Tilden,, K. Asanovich,, and J. S. Dumler. 1996. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 275:199205.
4. Bassily, S.,, K. C. Hyams,, N. A. el Masry,, Z. Farid,, E. Cross,, A. L. Bourgeois,, E. Ayad,, and R. G. Hibbs. 1994. Shortcourse norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt. Am. J. Trop. Med. Hyg. 51:219223.
5. Bella-Cueto, F.,, B. Font-Creus,, F. Segura-Porta,, E. Espejo- Arenas,, P. Lopez-Parez,, and T. Munoz-Espin. 1987. Comparative, randomized trial of one-day doxycycline versus 10-day tetracycline therapy for Mediterranean spotted fever.J. Infect. Dis. 155:10561058.
6. Bennish, M. L.,, M. A. Salam,, R. Haider,, and M. Barza. 1990. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J. Infect. Dis. 162:711716.
7. Bennish, M. L.,, M. A. Salam,, W. A. Khan,, and A. M. Khan. 1992. Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann. Intern. Med. 117:727734.
8. Bernard, E.,, M. Carles,, S. Politano,, C. Laffont,, and P. Dellamonica. 1989. Rickettsiosis caused by Rickettsia conorii: treatment with ofloxacin. Rev. Infect. Dis. 11.S989S991.
9. Bertrand, A.,, F. Janbon,, O. Jonquet,, and J. Reynes. 1988. Infections par les rickettsiales et fluoroquinolones. Pathol. Biol. 36:493495.
10. Brouqui, P.,, and D. Raoult. 1990. In vitro susceptibility of Ehrlichia sennetsu to antibiotics. Antimicrob. Agents Chemother. 34:15931596.
11. Brouqui, P.,, and D. Raoult. 1992. In vitro antibiotic susceptibility of the newly recognized agent of ehrhlichiosis in humans, Ehrlichia chaffeensis. Antimicrob. Agents Chemother. 36:27992803.
12. Brown, G. W.,, J. P. Saunders,, S. Singh,, D. L. Huxsoll,, and A. Shirai. 1978. Single dose doxycycline therapy for scrub typhus. Trans. R. Soc. Trop. Med. Hyg. 72:412416.
13. Brown, J. C.,, C. J. Thomson,, and S. G. Amyes. 1996. Mutations of the gyrA gene of clinical isolates of Salmonella typhimurium and three other Salmonella species leading to decreased susceptibilities to 4-quinolone drugs. J. Antimicrob. Chemother. 37:351356.
14. Brown, N. M.,, M. R. Millar,, J. A. Frost,, and B. Rowe. 1994. Ciprofloxacin resistance in Salmonella paratyphi A. J. Antimicrob. Chemother. 33:12581259.
15. Buitrago, M. I.,, J. W. Ijdo,, P. Rinaudo,, H. Simon,, J. Copel,, J. Gadbaw,, R. Heimer,, E. Fikrig,, and F. J. Bia. 1998. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin. Infect. Dis. 27:213215.
16. Caceres-Rios, H.,, J. Rodriguez-Tafur,, F. Bravo-Puccio,, C. Maguin-Avargas,, C. S. Diaz,, D. C. Ramos,, and R. Patarca. 1995. Verruga peruana: an infectious endemic angiomatosis. Crit. Rev. Oncog. 6:4756.
17. Chocarro, A.,, A. Gonzalez,, and I. Garcia. 2000. Treatment of tularemia with ciprofloxacin. Clin. Infect. Dis. 31:623.
18. Cooper, M. A.,, J. M. Andrews,, J. P. Ashby,, R. S. Matthews,, and R. Wise. 1990. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J. Antimicrob. Chemother. 26:667676.
19. Crowe, M.,, K. Ashford,, and P. Ispahani. 1996. Clinical features and antibiotic treatment of septic arthritis and osteomyelitis due to Yersinia enterocolitica. J. Med. Microbiol. 45:302309.
20. Daga, M. K.,, K. Sarin,, and R. Sarkar. 1994. A study of culture positive multidrug resistant enteric fever—changing pattern and emerging resistance to ciprofloxacin. /. Assoc. Physicians India 42:599600.
21. Dawson, J. E.,, B. E. Anderson,, D. B. Fishbein,, J. L. Sanchez,, C. S. Goldsmith,, K. H. Wilson,, and C. W. Duntley. 1991. Isolation and characterization of an Ehrlichia sp. from a patient diagnosed with human Ehrlichiosis. J. Clin. Microbiol. 29:27412745.
22. DeAbate, C. A.,, D. Henry,, G. Bensch,, A. Jubran,, S. Chodosh,, L. Harper,, D. Tipping,, and G. H. Talbot. 1998. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, doubleblind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. Chest 114:120130.
23. Donati, M.,, F. M. Rodriguez,, A. Olmo,, L. D'Apote,, and R. Cevenini. 1999. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J. Antimicrob. Chemother. 43:825827.
24. Donowitz, G. R.,, M. L. Brandon,, J. P. Salisbury,, C. P. Harman,, D. M. Tipping,, A. E. Urick,, and G. H. Talbot. 1997. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin. Ther. 19:936953.
25. Drancourt, M.,, and D. Raoult,. 1993. Methodology of antibiotics testing for intracellular pathogens, p. 7185. In D. Raoult (ed.), Antimicrobial Agents and Intracellular Pathogens. CRC Press, Boca Raton, Fla.
26. Dumler, J. S.,, and J. S. Bakken. 1995. Ehrlichial diseases of humans: emerging tick-borne infections. Clin. Infect. Dis. 20:11021110.
27. DuPont, H. L. 1991. Use of quinolones in the treatment of gastrointestinal infections. Eur. J. Clin. Microbiol. Infect. Dis. 10:325329.
28. DuPont, H. L. 1993. Quinolones in Salmonella typhi infection. Drugs 45(Suppl. 3):119124.
29. DuPont, H. L.,, C. D. Ericsson,, A. Robinson,, and P. C. Johnson. 1987. Current problems in antimicrobial therapy for bacterial enteric infection. Am. J. Med. 82:324328.
30. Edelstein, P. H.,, M. A. Edelstein,, and B. Holzknecht. 1992. In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 36:23872391.
31. Edelstein, P. H.,, M. A. Edelstein,, J. Weidenfeld,, and M. B. Dorr. 1990. In vitro activity of sparfloxacin (CI-978; AT- 4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 34:21222127.
32. Enderlin, G.,, L. Morales,, R. F. Jacobs,, and J. T. Cross. 1994. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin. Infect. Dis. 19:4247.
33. File, T. M., Jr. 1999. Levofloxacin in the treatment of community acquired pneumonia. Can. Respir. J. 6(Suppl. A):35A39A.
34. Fournier, P. E.,, H. Lelievre,, S. J. Eykyn,, J. L. Mainardi,, T. J. Marrie,, F. Bruneel,, C. Roure,, J. Nash,, D. Clave,, E. James,, C. Benoit-Lemercier,, L. Deforges,, H. Tissot-Dupont,, and D. Raoult. 2001. Epidemiologic and clinical characteristics of Bartonella quintana and Bartonellahenselae endocarditis: a study of 48 patients. Medicine (Baltimore) 80:245251.
35. Gant, V. A.,, G. Warnes,, I. Philips,, and G. F. Savidge. 1993. The application of flow cytometry to the study of bacterial responses to antibiotics. J. Med. Microbiol. 39:147154.
36. Garcia, I.,, A. Pascual,, S. Ballesta,, and E. J. Perea. 2000. Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells. Int. J. Antimicrob. Agents 15:201205.
37. Garcia, I.,, A. Pascual,, M. C. Conejo,, and E. J. Perea. 1996. [Intracellular penetration of 5 quinolones into non-phagocytic cells]. Enferm. Infecc. Microbiol. Clin. 14:167170.
38. Garcia, I.,, A. Pascual,, M. C. Guzman,, and E. J. Perea. 1992. Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob. Agents Chemother. 36:10531056.
39. Garcia, I.,, A. Pascual,, and E. J. Perea. 1994. Intracellular penetration and activity of BAY Y 3118 in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 38:24262429.
40. Garraffo, R.,, D. Jambou,, R. M. Chichmanian,, S. Ravoire,, and P. Lapalus. 1991. In vitro and in vivo ciprofloxacin pharmacokinetics in human neutrophils. Antimicrob. Agents Chemother. 35:22152218.
41. Gayraud, M.,, M. R. Scavizzi,, H. H. Mollaret,, L. Guillevin,, and M. J. Hornstein. 1993. Antibiotic treatment of Yersinia enterocolitica septicemia: a retrospective review of 43 cases. Clin. Infect. Dis. 17:405410.
42. Gentry, L. O. 1991. Review of quinolones in the treatment of infections of the skin and skin structure. J. Antimicrob. Chemother. 28(Suppl. C):97110.
43. Ghosh, A. S.,, J. Ahamed,, K. K. Chauhan,, and M. Kundu. 1998. Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae. Biochem. Biophys. Res. Commun. 242:5456.
44. Gikas, A.,, I. Spyridaki,, A. Psaroulaki,, D. Kofterithis,, and Y. Tselentis. 1999. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. Antimicrob. Agents Chemother. 42:27472748.
45. Goldberg, M. B.,, and R. H. Rubin. 1988. The spectrum of Salmonella infection. Infect. Dis. Clin. N. Am. 2:571598.
46. Gudiol, F.,, R. Pallares,, J. Carratala,, F. Bolao,, J. Ariza,, G. Rufi,, and P. F. Viladrich. 1989. Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever. Antimicrob. Agents Chemother. 33:987988.
47. Hall, W. H. 1990. Modern chemotherapy for brucellosis in humans. Rev. Infect. Dis. 12:10601099.
48. Hammerschlag, M. R. 1999. Activity of quinolones against Chlamydia pneumoniae . Drugs 58(Suppl. 2):7881.
49. Hammerschlag, M. R. 2000. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review. J. Antimicrob. Chemother. 45(Suppl. l):3539.
50. Hoogkamp-Korstanje, J. A. 1987. Antibiotics in Yersinia enterocolitica infections.J. Antimicrob. Chemother. 20:123131.
51. Huys, J.,, J. Kayhigi,, P. Freyens,, and G. V. Berghe. 1973. Single-dose treatment of epidemic typhus with doxycyline. Chemotherapy 18:314317.
52. Dcaheimo, I.,, H. Syrjala,, J. Karhukorpi,, R. Schildt,, and M. Koskela. 2000. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J. Antimicrob. Chemother. 46:287290.
53. Jackson, L. A.,, and J. T. Grayston,. 1998. Chlamydia pneumoniae , p. 583586. In V. L. Yu,, T. C. Merigan, Jr.,, and S. L. Barriere. (ed.), Antimicrobial Therapy and Vaccines. Williams and Wilkins, Baltimore, Md.
54. Janbon, F.,, O. Jonquet,, J. Reynes,, and A. Bertrand. 1989. Use of pefloxacin in the treatment of Rickettsiosis and Coxiellosis. Rev. Infect. Dis. 11:990991.
55. Jeskanen, L.,, L. Karppinen,, L. Ingervo,, S. Reitamo,, H. P. Happonen,, and A. Lassus. 1989. Ciprofloxacin versus doxycycline in the treatment of uncomplicated urogenital Chlamydia trachomatis infections. A double-blind comparative study. Scand. J. Infect. Dis. Suppl. 60:6265.
56. Kelly, D. J.,, K. F. Salata,, D. Strickman,, and J. N. Hershey. 1995. Rickettsia tsutsugamushi infection in cell culture: antibiotic susceptibility determined by flow cytometry. Am. J. Trop. Med. Hyg. 53:602606.
57. Keren, G.,, A. Keysary,, R. Goldwasser,, and E. Rubinstein. 1994. The inhibitory effect of fluoroquinolones on Coxiella burnetii growth in in-vitro systems. /. Antimicrob. Chemother. 33:12541255.
58. Khan, W. A.,, C. Seas,, U. Dhar,, M. A. Salam,, and M. L. Bennish. 1997. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann. Intern. Med. 126:697703.
59. Kitsukawa, K.,, J. Hara,, and A. Saito. 1991. Inhibition of Legionella pneumophila in Guinea pig peritoneal macrophages by new quinolones, macrolides and other antimicrobial agents. J. Antimicrob. Chemother. 27:343353.
60. Klein, M. B.,, C. M. Nelson,, and J. L. Goodman. 1997. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob. Agents Chemother. 41:7679.
61. Kurz, R. W.,, W. Graninger,, T. P. Egger,, H. Pichler,, and K. H. Tragi. 1988. Failure of treatment of Legionella pneumonophila with ciprofloxacin. J. Antimicrob. Chemother. 22:389391.
62. Lang, R.,, and E. Rubinstein. 1992. Quinolones for the treatment of brucellosis. J. Antimicrob. Chemother. 29:357360.
63. Limaye, A. P.,, and C. J. Hooper. 1999. Treatment of tularemia with fluoroquinolones: two cases and review. Clin. Infect. Dis. 29:922924.
64. Lipsky, P. E., 1994. Rheumatoid arthritis, p. 16481653. In K. J. Isselbacher,, E. Braunwald,, J. D. Wilson,, J. B. Martin,, A. S. Fauci,, and D. L. Kasper (ed.), Harrisson's Principles of Internal Medicine. Mc Graw-Hill, Inc., New York, N.Y.
65. Maurin, M.,, C. Abergel,, and D. Raoult. 2001. DNA gyrasemediated natural resistance to fluoroquinolones in Ehrlichia spp. Antimicrob. Agents Chemother. 45:20982105.
66. Maurin, M.,, A. M. Benoliel,, P. Bongrand,, and D. Raoult. 1992. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J. Infect. Dis. 166:10971102.
67. Maurin, M.,, N. F. Mersali,, and D. Raoult. 2000. Bactericidal activities of antibiotics against intracellular Francisella tularensis. Antimicrob. Agents Chemother. 44:34283431.
68. Maurin, M.,, and D. Raoult. 1994. Phagolysosomal alkalinization and intracellular killing of Staphylococcus aureus by amikacin. J. Infect. Dis. 169:330336.
69. Maurin, M.,, and D. Raoult. 1996. Optimum treatment of intracellular infection. Drugs 52:4559.
70. Maurin, M.,, and D. Raoult. 1997. Bacteriostatic and bactericidal activity of levofloxacin against Rickettsia rickettsii, Rickettsia conorii , "Israeli spotted fever group rickettsia" and Coxiella burnetii. J. Antimicrob. Chemother. 39:725730.
71. Maurin, M.,, and D. Raoult. 1999. Q fever. Clin. Microbiol. Rev. 12:518553.
72. Musso, D.,, M. Drancourt,, S. Osscini,, and D. Raoult. 1996. Sequence of quinolone resistance-determining region of gyrA gene for clinical isolates and for an in vitro-selected quinolone-resistant strain of Coxiella burnetii. Antimicrob. Agents Chemother. 40:870873.
73. Nagayama, A.,, T. Nakao,, and H. Taen. 1988. In vitro activities of ofloxacin and four other new quinoline- carboxylic acids against Chlamydia trachomatis. Antimicrob. Agents Chemother. 32:17351737.
74. Oriel, J. D. 1989. Use of quinolones in chlamydial infection. Rev. Infect. Dis. 11(Suppl. 5):S1273S1276
75. Ozaki, M.,, K. Komori,, M. Matsuda,, R. Yamaguchi,, T. Honmura,, Y. Tomii,, I. Nishimura,, and T. Nishino. 1996. Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 40:739742.
76. Pascual, A.,, I. Garcia,, S. Ballesta,, and E. J. Perea. 1997. Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells. Antimicrob. Agents Chemother. 41:274277.
77. Pascual, A.,, I. Garcia,, S. Ballesta,, and E. J. Perea. 1999. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob. Agents Chemother. 43:1215.
78. Pascual, A.,, I. Garcia,, M. C. Conejo,, and E. J. Perea. 1991. Fluorometric and high-performance liquid chromatographic measurement of quinolone uptake by human neutrophils. Eur.J. Clin. Microbiol. Infect. Dis. 10:969971.
79. Pascual, A.,, I. Garcia,, and E. J. Perea. 1992. Entry of lomefloxacin and temafloxacin into human neutrophils, peritoneal macrophages, and tissue culture cells. Diagn. Microbiol. Infect. Dis. 15:393398.
80. Perea, E. J.,, I. Garcia,, and A. Pascual. 1992. Comparative penetration of lomefloxacin and other quinolones into human phagocytes. Am. J. Med. 92:48S51S.
81. Perine, P. L.,, D. W. Krause,, S. Awoke,, and J. E. McDade. 1974. Single-dose doxycycline treatment of louse-borne relapsing fever and epidemic typhus. Lancet ii:742744.
82. Raoult, D.,, P. Bres,, M. Drancourt,, and G. Vestris. 1991. In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii , and Rickettsia conorii to the fluoroquinolone sparfloxacin. Antimicrob. Agents Chemother. 35:8891.
83. Raoult, D.,, H. Gallais,, P. De Micco,, and P. Casanova. 1986. Ciprofloxacin therapy for Mediterranean spotted fever. Antimicrob. Agents Chemother. 30:606607.
84. Raoult, D.,, J. B. Ndihokubwayo,, H. Tissot-Dupont,, V. Roux,, B. Faugere,, R. Abegbinni,, and R. J. Birtles. 1998. Outbreak of epidemic typhus associated with trench fever in Burundi. Lancet 352:353358.
85. Raoult, D.,, and J. G. Olson,. 1999. Emerging rickettsioses, p. 1735. In W. M. Scheld,, W. A. Craig,, and J. M. Hughes (ed.), Emerging Infections 3. ASM Press, Washington, D.C.
86. Raoult, D.,, H. Tissot-Dupont,, C. Foucault,, J. Gouvernet,, P. E. Fournier,, E. Bernit,, A. Stein,, M. Nesri,, J. R. Harle,, and P. J. Weiller. 2000. Q fever 1985-1998: clinical and epidemiologic features of 1,383 infections. Medicine 79:109123.
87. Raoult, D.,, H. Torres,, and M. Drancourt. 1991. Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii . Antimicrob. Agents Chemother. 35:20702077.
88. Raoult, D.,, M. Yeaman,, and O. Baca. 1989. Susceptibility of Rickettsia and Coxiella burnetii to quinolones. Rev. Infect. Dis. 11:986
89. Raoult, D.,, M. R. Yeaman,, and O. G. Baca. 1989. Susceptibility of Coxiella burnetii to pefloxacin and ofloxacin in ovo and persistently infected L929 cells. Antimicrob. Agents Chemother. 33:621623.
90. Roblin, P. M.,, G. Montalban,, and M. R. Hammerschlag. 1994. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 38:14021403.
91. Rolain, J. M.,, M. Maurin,, and D. Raoult. 2001. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii. Antimicrob. Agents Chemother. 45:301302.
92. Rolain, J. M.,, M. Maurin,, G. Vestris,, and D. Raoult. 1998. In vitro susceptibilities of 27 Rickettsiae to 13 antimicrobials. Antimicrob. Agents Chemother. 42:15371541.
93. Rowe, B.,, L. R. Ward,, and E. J. Threlfall. 1995. Ciprofloxacinresistant Salmonella typhi in the UK. Lancet 346:1302.
94. Salam, M. A.,, and M. L. Bennish. 1991. Antimicrobial therapy for shigellosis. Rev. Infect. Dis. 13(Suppl. 4):S332S341.
95. Scheel, O.,, R. Reiersen,, and T. Hoel. 1992. Treatment of tularemia with ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 11:447448.
96. Schlick, W. 1993. The problems of treating atypical pneumonia. J. Antimicrob. Chemother. 31(Suppl. C):lll120.
97. Stanley, P. J.,, P. J. Flegg,, B. K. Mandal,, and A. M. Geddes. 1989. Open study of ciprofloxacin in enteric fever. J. Antimicrob. Chemother. 23:789791.
98. Stout, J. E.,, B. Arnold,, and V. L. Yu. 1998. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. Diagn. Microbiol. Infect. Dis. 30:3743.
99. Syrjala, H.,, R. Schildt,, and S. Raisainen. 1991. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 10:6870.
100. Toomey, K. E.,, and R. C. Barnes. 1990. Treatment of Chlamydia trachomatis genital infection. Rev. Infect. Dis. 12(Suppl. 6):S645S655.
101. Topkis, S.,, H. Swarz,, S. A. Breisch,, and A. N. Maroli. 1997. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia. Clin. Ther. 19:975988.
102. Unertl, K. E.,, F. P. Lenhart,, H. Forst,, G. Vogler,, V. Wilm,, W. Ehret,, and G. Ruckdeschel. 1989. Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin. Am. J. Med. 87:128S131S.
103. Vergis, E. N.,, and V. L. Yu,. 1998. Legionella species, p. 257272. In V. L. Yu,, T. C. Merigan, Jr.,, and S. L. Barriere (ed.), Antimicrobial Therapy and Vaccines. Williams and Wilkins, Baltimore, Md.
104. Wain, J.,, N. T. Hoa,, N. T. Chinh,, H. Vinh,, M. J. Everett,, T. S. Diep,, N. P. Day,, T. Solomon,, N. J. White,, L. J. Piddock,, and C. M. Parry. 1997. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin. Infect. Dis. 25:14041410.
105. Waiz, A. 1995. The new quinolones in the treatment of diarrhea and typhoid fever. Drugs 49(Suppl. 2):132135.
106. Walker, D. H.,, and J. S. Dumler. 1996. Emergence of the ehrlichioses as human health problems. Emerg. Infect. Dis. 2:115.
107. Weiss, E.,, and H. R. Dressier. 1960. Centrifugation of rickettsiae and viruses into cells and its effect on infection. Proc. Soc. Exp. Biol. Med. 103:691695.
108. White, N. J., 1998. Salmonella typhi and paratyphi , p. 361376. In V. L. Yu,, T. C. Merigan, Jr.,, and S. L. Barriere (ed.), Antimicrobial Therapy and Vaccines , Williams and Wilkins, Baltimore, Md.
109. Willke, A. 2000. Low-level resistance to fluoroquinolones among Salmonella and Shigella . Clin. Microbiol. Infect. 6:687.
110. Yeaman, M. R.,, L. A. Mitscher,, and O. G. Baca. 1987. In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones. Antimicrob. Agents Chemother. 31:10791084.

Tables

Generic image for table
Table 1

Target cells and subcellular localization of intracellular bacteria

Citation: Rolain J, Raoult D. 2003. Treatment of Intracellular Infections, p 323-335. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch20
Generic image for table
Table 2

Antibiotic uptake, subcellular localization, and pH of optimum activity of antibiotics

Citation: Rolain J, Raoult D. 2003. Treatment of Intracellular Infections, p 323-335. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch20
Generic image for table
Table 3

Antibiotic susceptibility of obligate intracellular bacteria, as determined using in vitro cell models

Citation: Rolain J, Raoult D. 2003. Treatment of Intracellular Infections, p 323-335. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch20
Generic image for table
Table 4

Antibiotic treatment recommendations for intracellular pathogens

Citation: Rolain J, Raoult D. 2003. Treatment of Intracellular Infections, p 323-335. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch20

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error